Tags

Type your tag names separated by a space and hit enter

Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
Am J Cardiol. 2005 Nov 07; 96(9A):20K-27K; discussion 34K-35K.AJ

Abstract

Despite a growing body of research on the benefit of combination drug therapy for dyslipidemia in the metabolic syndrome or diabetes mellitus, there are insufficient outcome data on the use of combination therapy as well as inadequate data to compare certain combination regimens. The focus of the therapeutic approach in treating the metabolic syndrome has been almost exclusively on low-density lipoprotein (LDL) cholesterol for approximately the past 10 years, and specifically on statin therapy. Although results of epidemiologic studies as well as clinical trials using angiographic and clinical end points confirm the association of LDL cholesterol and risk of coronary artery disease, data are lacking regarding the effects of combination therapy in the management of coronary artery disease. Management of the metabolic syndrome focusing on the modification of plasma LDL as well as high-density lipoprotein cholesterol is reviewed. Future management strategies with the use of novel combination therapy is also discussed.

Authors+Show Affiliations

Kastelein JJ
Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. e.vandongen@amc.uva.nl

MeSH

Carrier ProteinsCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, LDLClofibric AcidCoronary DiseaseDrug Therapy, CombinationDyslipidemiasFatty Acids, Omega-3GlycoproteinsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMetabolic SyndromeNiacin

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16291010

Citation

Kastelein, John J P.. "Modifying Plasma Low-density Lipoprotein and High-density Lipoprotein Cholesterol: what Combinations Are Available in the Future?" The American Journal of Cardiology, vol. 96, no. 9A, 2005, 20K-27K; discussion 34K-35K.
Kastelein JJ. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future? Am J Cardiol. 2005;96(9A):20K-27K; discussion 34K-35K.
Kastelein, J. J. (2005). Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future? The American Journal of Cardiology, 96(9A), 20K-27K; discussion 34K-35K.
Kastelein JJ. Modifying Plasma Low-density Lipoprotein and High-density Lipoprotein Cholesterol: what Combinations Are Available in the Future. Am J Cardiol. 2005 Nov 7;96(9A):20K-27K; discussion 34K-35K. PubMed PMID: 16291010.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future? A1 - Kastelein,John J P, Y1 - 2005/09/21/ PY - 2005/11/18/pubmed PY - 2005/12/16/medline PY - 2005/11/18/entrez SP - 20K-27K; discussion 34K-35K JF - The American journal of cardiology JO - Am J Cardiol VL - 96 IS - 9A N2 - Despite a growing body of research on the benefit of combination drug therapy for dyslipidemia in the metabolic syndrome or diabetes mellitus, there are insufficient outcome data on the use of combination therapy as well as inadequate data to compare certain combination regimens. The focus of the therapeutic approach in treating the metabolic syndrome has been almost exclusively on low-density lipoprotein (LDL) cholesterol for approximately the past 10 years, and specifically on statin therapy. Although results of epidemiologic studies as well as clinical trials using angiographic and clinical end points confirm the association of LDL cholesterol and risk of coronary artery disease, data are lacking regarding the effects of combination therapy in the management of coronary artery disease. Management of the metabolic syndrome focusing on the modification of plasma LDL as well as high-density lipoprotein cholesterol is reviewed. Future management strategies with the use of novel combination therapy is also discussed. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/16291010/Modifying_plasma_low_density_lipoprotein_and_high_density_lipoprotein_cholesterol:_what_combinations_are_available_in_the_future DB - PRIME DP - Unbound Medicine ER -